CD4 T cell differentiation in type 1 diabetes

Clinical and Experimental Immunology

Volumn 183, Issue 1, 2016, Pages 16-29

  Walker, L S K ^a   von Herrath, M ^b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c NOVO NORDISK INC   (United States)

Author keywords

Cytokine differentiation; Diabetes; T cells

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 21; HLA ANTIGEN; INTERLEUKIN DERIVATIVE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FATE; CELL INTERACTION; CELL MIGRATION; CYTOKINE PRODUCTION; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MOUSE; T LYMPHOCYTE SUBPOPULATION; TH1 TH2 BALANCE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DIABETES MELLITUS, TYPE 1; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; INTERLEUKIN-17; INTERLEUKINS; MICE; T-LYMPHOCYTE SUBSETS; TH1-TH2 BALANCE;

EID: 84955278186     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12672     Document Type: Article

References (161)

1. Todd JA. Etiology of type 1 diabetes. Immunity 2010; 32:457-67.
2. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004; 4:595-602.
3. Vahedi G, Kanno Y, Furumoto Y et al. Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature 2015; 520: 558-62.
4. Hnisz D, Abraham BJ, Lee TI et al. Super-enhancers in the control of cell identity and disease. Cell 2013; 155:934-47.
5. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995; 268:1185-8.
6. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes 1994; 43:613-21.
7. von Herrath MG, Oldstone MB. Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med 1997; 185:531-9.
8. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145-73.
9. Rapoport MJ, Jaramillo A, Zipris D et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178:87-99.
10. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996; 184:1093-9.
11. Zaccone P, Cooke A. Helminth mediated modulation of type 1 diabetes (T1D). Int J Parasitol 2013; 43:311-8.
12. Sarvetnick N, Liggitt D, Pitts SL, Hansen SE, Stewart TA. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. Cell 1988; 52:773-82.
13. Debray-Sachs M, Carnaud C, Boitard C et al. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J Autoimmun 1991; 4:237-48.
14. Campbell IL, Kay TW, Oxbrow L, Harrison LC. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 1991; 87:739-42.
15. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75:163-89.
16. Savinov AY, Wong FS, Chervonsky AV. IFN-gamma affects homing of diabetogenic T cells. J Immunol 2001; 167:6637-43.
17. Chong MM, Thomas HE, Kay TW. Gamma-interferon signaling in pancreatic beta-cells is persistent but can be terminated by overexpression of suppressor of cytokine signaling-1. Diabetes 2001; 50:2744-51.
18. Barral AM, Thomas HE, Ling EM et al. SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes. J Autoimmun 2006; 27:166-73.
19. Yi Z, Li L, Garland A et al. IFN-gamma receptor deficiency prevents diabetes induction by diabetogenic CD4+, but not CD8+, T cells. Eur J Immunol 2012; 42:2010-8.
20. Arif S, Tree TI, Astill TP et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113:451-63.
21. Petrich de Marquesini LG, Fu J, Connor KJ et al. IFN-gamma and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia 2010; 53:1451-60.
22. Han D, Leyva CA, Matheson D et al. Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. Clin Immunol 2011; 139:290-301.
23. Anderson JT, Cornelius JG, Jarpe AJ, et al. Insulin-dependent diabetes in the NOD mouse model. II. Beta cell destruction in autoimmune diabetes is a TH2 and not a TH1 mediated event. Autoimmunity 1993; 15:113-22.
24. Azar ST, Tamim H, Beyhum HN, Habbal MZ, Almawi WY. Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease. Clin Diagn Lab Immunol 1999; 6:306-10.
25. Poulin M, Haskins K. Induction of diabetes in nonobese diabetic mice by Th2 T cell clones from a TCR transgenic mouse. J Immunol 2000; 164:3072-8.
26. Mishra PK, Patel N, Wu W, Bleich D, Gause WC. Prevention of type 1 diabetes through infection with an intestinal nematode parasite requires IL-10 in the absence of a Th2-type response. Mucosal Immunol 2013; 6:297-308.
27. Hubner MP, Shi Y, Torrero MN et al. Helminth protection against autoimmune diabetes in nonobese diabetic mice is independent of a type 2 immune shift and requires TGF-beta. J Immunol 2012; 188:559-68.
28. Wang B, Andre I, Gonzalez A et al. Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94:13844-9.
29. Kanagawa O, Xu G, Tevaarwerk A, Vaupel BA. Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor loci. J Immunol 2000; 164:3919-23.
30. Serreze DV, Post CM, Chapman HD, Johnson EA, Lu B, Rothman PB. Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes 2000; 49:2007-11.
31. Hultgren B, Huang X, Dybdal N, Stewart TA. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 1996; 45:812-7.
32. Wang B, Gonzalez A, Hoglund P, Katz JD, Benoist C, Mathis D. Interleukin-4 deficiency does not exacerbate disease in NOD mice. Diabetes 1998; 47:1207-11.
33. Satoh J, Seino H, Abo T et al. Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 1989; 84:1345-8.
34. Sobel DO, Han J, Williams J, Yoon JW, Jun HS, Ahvazi B. Gamma interferon paradoxically inhibits the development of diabetes in the NOD mouse. J Autoimmun 2002; 19:129-37.
35. Fousteri G, Dave A, Bot A, Juntti T, Omid S, von Herrath M. Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma. Diabetologia 2010; 53:1958-70.
36. Serreze DV, Chapman HD, Post CM, Johnson EA, Suarez-Pinzon WL, Rabinovitch A. Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J Immunol 2001; 166:1352-9.
37. Kent SC, Chen Y, Bregoli L et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005; 435:224-8.
38. Halminen M, Simell O, Knip M, Ilonen J. Cytokine expression in unstimulated PBMC of children with type 1 diabetes and subjects positive for diabetes-associated autoantibodies. Scand J Immunol 2001; 53:510-3.
39. Kukreja A, Cost G, Marker J et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109:131-40.
40. Karlsson Faresjo MG, Ernerudh J, Ludvigsson J. Cytokine profile in children during the first 3 months after the diagnosis of type 1 diabetes. Scand J Immunol 2004; 59:517-26.
41. Chatzigeorgiou A, Harokopos V, Mylona-Karagianni C, Tsouvalas E, Aidinis V, Kamper EF. The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time. Ann Med 2010; 42:426-38.
42. Strom A, Menart B, Simon MC et al. Cellular interferon-gamma and interleukin-13 immune reactivity in type 1, type 2 and latent autoimmune diabetes: action LADA 6. Cytokine 2012; 58:148-51.
43. Karlsson MG, Lawesson SS, Ludvigsson J. Th1-like dominance in high-risk first-degree relatives of type I diabetic patients. Diabetologia 2000; 43:742-9.
44. Karlsson Faresjo MG, Ludvigsson J. Diminished Th1-like response to autoantigens in children with a high risk of developing type 1 diabetes. Scand J Immunol 2005; 61:173-9.
45. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6:1133-41.
46. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1123-32.
47. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13:139-45.
48. Jain R, Tartar DM, Gregg RK et al. Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med 2008; 205:207-18.
49. Emamaullee JA, Davis J, Merani S et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009; 58:1302-11.
50. Joseph J, Bittner S, Kaiser FM, Wiendl H, Kissler S. IL-17 silencing does not protect nonobese diabetic mice from autoimmune diabetes. J Immunol 2012; 188:216-21.
51. Kriegel MA, Sefik E, Hill JA, Wu HJ, Benoist C, Mathis D. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc Natl Acad Sci USA 2011; 108:11548-53.
52. Ivanov, II, Atarashi K, Manel N et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139:485-98.
53. Lau K, Benitez P, Ardissone A et al. Inhibition of type 1 diabetes correlated to a Lactobacillus johnsonii N6.2-mediated Th17 bias. J Immunol 2011; 186:3538-46.
54. Nikoopour E, Schwartz JA, Huszarik K et al. Th17 polarized cells from nonobese diabetic mice following mycobacterial adjuvant immunotherapy delay type 1 diabetes. J Immunol 2010; 184:4779-88.
55. Bending D, De la Pena H, Veldhoen M et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009; 119:565-72.
56. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 2009; 39:216-24.
57. Liu SM, Lee DH, Sullivan JM et al. Differential IL-21 signaling in APCs leads to disparate Th17 differentiation in diabetes-susceptible NOD and diabetes-resistant NOD.Idd3 mice. J Clin Invest 2011; 121:4303-10.
58. Li CR, Mueller EE, Bradley LM. Islet antigen-specific Th17 cells can induce TNF-alpha-dependent autoimmune diabetes. J Immunol 2014; 192:1425-32.
59. Vukkadapu SS, Belli JM, Ishii K et al. Dynamic interaction between T cell-mediated beta-cell damage and beta-cell repair in the run up to autoimmune diabetes of the NOD mouse. Physiol Genomics 2005; 21:201-11.
60. Honkanen J, Nieminen JK, Gao R et al. IL-17 immunity in human type 1 diabetes. J Immunol 2010; 185:1959-67.
61. Marwaha AK, Crome SQ, Panagiotopoulos C et al. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol 2010; 185:3814-8.
62. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8:942-9.
63. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950-7.
64. Bradshaw EM, Raddassi K, Elyaman W et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol 2009; 183:4432-9.
65. Wong FS, Wen L. Therapy: immunotherapy for T1DM - targeting innate immunity. Nat Rev Endocrinol 2013; 9:384-5.
66. Ferraro A, Socci C, Stabilini A et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011; 60:2903-13.
67. Ferreira RC, Simons HZ, Thompson WS et al. IL-21 production by CD4 effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. Diabetologia 2015; 58:781-90.
68. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204:1849-61.
69. Ahern PP, Schiering C, Buonocore S et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 2010; 33:279-88.
70. Hirota K, Duarte JH, Veldhoen M et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 2011; 12:255-63.
71. Reinert-Hartwall L, Honkanen J, Salo HM et al. Th1/Th17 plasticity is a marker of advanced beta cell autoimmunity and impaired glucose tolerance in humans. J Immunol 2015; 194:68-75.
72. Arif S, Moore F, Marks K et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes 2011; 60:2112-9.
73. Zhernakova A, Alizadeh BZ, Bevova M et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet 2007; 81:1284-8.
74. Todd JA, Walker NM, Cooper JD et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39:857-64.
75. McGuire HM, Vogelzang A, Hill N, Flodstrom-Tullberg M, Sprent J, King C. Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus. Proc Natl Acad Sci USA 2009; 106:19438-43.
76. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117:265-77.
77. Clough LE, Wang CJ, Schmidt EM et al. Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J Immunol 2008; 180:5393-401.
78. Sutherland AP, Van Belle T, Wurster AL et al. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 2009; 58:1144-55.
79. Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci USA 2008; 105:14028-33.
80. Korn T, Bettelli E, Gao W et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448:484-7.
81. Wei L, Laurence A, Elias KM, O'Shea JJ. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 2007; 282:34605-10.
82. Nurieva R, Yang XO, Martinez G et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448:480-3.
83. McGuire HM, Walters S, Vogelzang A et al. Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 2011; 60:867-75.
84. McGuire HM, Vogelzang A, Ma CS et al. A subset of interleukin-21+ chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity. Immunity 2011; 34:602-15.
85. Van Belle TL, Nierkens S, Arens R, von Herrath MG. Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. Immunity 2012; 36:1060-72.
86. + T cell proliferation by murine macrophages. Clin Exp Immunol 2008; 151:487-95.
87. Peluso I, Fantini MC, Fina D et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007; 178:732-9.
88. Attridge K, Wang CJ, Wardzinski L et al. IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood 2012; 119:4656-64.
89. hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol 2008; 154:353-9.
90. Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner J. The effector T cells of diabetic subjects are resistant to regulation via CD4+FOXP3+ regulatory T cells. J Immunol 2008; 181:7350-5.
91. Walker LS. Regulatory T cells overturned: the effectors fight back. Immunology 2009; 126:466-74.
92. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-52.
93. Wong FS, Wen L, Tang M et al. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes 2004; 53:2581-7.
94. Smith MJ, Packard TA, O'Neill SK et al. Loss of anergic B cells in pre-diabetic and new onset T1D patients. Diabetes 2014; 64:1703-12.
95. Ozaki K, Spolski R, Ettinger R et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 2004; 173:5361-71.
96. Ettinger R, Sims GP, Fairhurst AM et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005; 175:7867-79.
97. Zotos D, Coquet JM, Zhang Y et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med 2010; 207:365-78.
98. Linterman MA, Beaton L, Yu D et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med 2010; 207:353-63.
99. Attridge K, Kenefeck R, Wardzinski L et al. IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells. J Immunol 2014; 192:2195-201.
100. Salek-Ardakani S, Choi YS, Rafii-El-Idrissi Benhnia M et al. B cell-specific expression of B7-2 is required for follicular Th cell function in response to vaccinia virus. J Immunol 2011; 186:5294-303.
101. Thompson WS, Pekalski ML, Simons HZ et al. Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes. Clin Exp Immunol 2014; 177:571-85.
102. Brandt K, Bulfone-Paus S, Foster DC, Ruckert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003; 102:4090-8.
103. Wan CK, Oh J, Li P et al. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 2013; 38:514-27.
104. Mehta DS, Wurster AL, Whitters MJ, Young DA, Collins M, Grusby MJ. IL-21 induces the apoptosis of resting and activated primary B cells. J Immunol 2003; 170:4111-8.
105. Jin H, Carrio R, Yu A, Malek TR. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 2004; 173:657-65.
106. Kenefeck R, Wang CJ, Kapadi T et al. Follicular helper T cell signature in type 1 diabetes. J Clin Invest 2015; 125:292-303.
107. Xu X, Shi Y, Cai Y et al. Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. PLOS ONE 2013; 8:e79858.
108. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005; 5:853-65.
109. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011; 29:621-63.
110. Pot C, Jin H, Awasthi A et al. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J Immunol 2009; 183:797-801.
111. Schmitt N, Bentebibel SE, Ueno H. Phenotype and functions of memory Tfh cells in human blood. Trends Immunol 2014; 35:436-42.
112. Luthje K, Kallies A, Shimohakamada Y et al. The development and fate of follicular helper T cells defined by an IL-21 reporter mouse. Nat Immunol 2012; 13:491-8.
113. Liu X, Yan X, Zhong B et al. Bcl6 expression specifies the T follicular helper cell program in vivo. J Exp Med 2012; 209:1841-52, S1-24.
114. Weber JP, Fuhrmann F, Hutloff A. T-follicular helper cells survive as long-term memory cells. Eur J Immunol 2012; 42:1981-8.
115. Choi YS, Yang JA, Yusuf I et al. Bcl6 expressing follicular helper CD4 T cells are fate committed early and have the capacity to form memory. J Immunol 2013; 190:4014-26.
116. Hale JS, Youngblood B, Latner DR et al. Distinct memory CD4+ T cells with commitment to T follicular helper- and T helper 1-cell lineages are generated after acute viral infection. Immunity 2013; 38:805-17.
117. Baumjohann D, Preite S, Reboldi A et al. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 2013; 38:596-605.
118. He J, Tsai LM, Leong YA et al. Circulating precursor CCR7(lo)PD-1(hi) CXCR5(+) CD4(+) T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 2013; 39:770-81.
119. Shulman Z, Gitlin AD, Targ S et al. T follicular helper cell dynamics in germinal centers. Science 2013; 341:673-7.
120. Sage PT, Alvarez D, Godec J, von Andrian UH, Sharpe AH. Circulating T follicular regulatory and helper cells have memory-like properties. J Clin Invest 2014; 124:5191-204.
121. Ziegler AG, Rewers M, Simell O et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309:2473-9.
122. Steck AK, Vehik K, Bonifacio E et al. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: the environmental determinants of diabetes in the young (TEDDY). Diabetes Care 2015; 38:808-13.
123. Skarstrand H, Krupinska E, Haataja TJ, Vaziri-Sani F, Lagerstedt JO, Lernmark A. Zinc transporter 8 (ZnT8) autoantibody epitope specificity and affinity examined with recombinant ZnT8 variant proteins in specific ZnT8R and ZnT8W autoantibody-positive type 1 diabetes patients. Clin Exp Immunol 2015; 179:220-9.
124. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004; 114:589-97.
125. Curnock RM, Reed CR, Rokni S, Broadhurst JW, Bingley PJ, Williams AJ. Insulin autoantibody affinity measurement using a single concentration of unlabelled insulin competitor discriminates risk in relatives of patients with type 1 diabetes. Clin Exp Immunol 2012; 167:67-72.
126. Bender C, Schlosser M, Christen U, Ziegler AG, Achenbach P. GAD autoantibody affinity in schoolchildren from the general population. Diabetologia 2014; 57:1911-8.
127. Choi YS, Kageyama R, Eto D et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 2011; 34:932-46.
128. Pepper M, Pagan AJ, Igyarto BZ, Taylor JJ, Jenkins MK. Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. Immunity 2011; 35:583-95.
129. Johnston RJ, Choi YS, Diamond JA, Yang JA, Crotty S. STAT5 is a potent negative regulator of TFH cell differentiation. J Exp Med 2012; 209:243-50.
130. Ballesteros-Tato A, Leon B, Graf BA et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 2012; 36:847-56.
131. Oestreich KJ, Mohn SE, Weinmann AS. Molecular mechanisms that control the expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene profile. Nat Immunol 2012; 13:405-11.
132. Lowe CE, Cooper JD, Brusko T et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007; 39:1074-82.
133. Dendrou CA, Plagnol V, Fung E et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 2009; 41:1011-5.
134. Long SA, Cerosaletti K, Bollyky PL et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010; 59:407-15.
135. Garg G, Tyler JR, Yang JH et al. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol 2012; 188:4644-53.
136. Hulme MA, Wasserfall CH, Atkinson MA, Brusko TM. Central role for interleukin-2 in type 1 diabetes. Diabetes 2012; 61:14-22.
137. Silva DG, Daley SR, Hogan J et al. Anti-islet autoantibodies trigger autoimmune diabetes in the presence of an increased frequency of islet-reactive CD4 T cells. Diabetes 2011; 60:2102-11.
138. Luzina IG, Atamas SP, Storrer CE et al. Spontaneous formation of germinal centers in autoimmune mice. J Leukoc Biol 2001; 70:578-84.
139. Kendall PL, Yu G, Woodward EJ, Thomas JW. Tertiary lymphoid structures in the pancreas promote selection of B lymphocytes in autoimmune diabetes. J Immunol 2007; 178:5643-51.
140. Astorri E, Bombardieri M, Gabba S, Peakman M, Pozzilli P, Pitzalis C. Evolution of ectopic lymphoid neogenesis and in situ autoantibody production in autoimmune nonobese diabetic mice: cellular and molecular characterization of tertiary lymphoid structures in pancreatic islets. J Immunol 2010; 185:3359-68.
141. Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 2009; 10:385-93.
142. Perreau M, Savoye AL, De Crignis E et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013; 210:143-56.
143. Deenick EK, Chan A, Ma CS et al. Follicular helper T cell differentiation requires continuous antigen presentation that is independent of unique B cell signaling. Immunity 2010; 33:241-53.
144. Wing JB, Ise W, Kurosaki T, Sakaguchi S. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 2014; 41:1013-25.
145. Sage PT, Paterson AM, Lovitch SB, Sharpe AH. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 2014; 41:1026-39.
146. Wang CJ, Heuts F, Ovcinnikovs V et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci USA 2015; 112:524-9.
147. Linterman MA, Denton AE, Divekar DP et al. CD28 expression is required after T cell priming for helper T cell responses and protective immunity to infection. Elife 2014; 3. doi:10.7554/eLife.03180.
148. Linterman MA, Vinuesa CG. Signals that influence T follicular helper cell differentiation and function. Semin Immunopathol 2010; 32:183-96.
149. Walker LS, Wiggett HE, Gaspal FM et al. Established T cell-driven germinal center B cell proliferation is independent of CD28 signaling but is tightly regulated through CTLA-4. J Immunol 2003; 170:91-8.
150. Walker LS, Gulbranson-Judge A, Flynn S et al. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J Exp Med 1999; 190:1115-22.
151. Maine CJ, Marquardt K, Cheung J, Sherman LA. PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells. J Immunol 2014; 192:1415-24.
152. Becattini S, Latorre D, Mele F et al. T cell immunity. Functional heterogeneity of human memory CD4(+) T cell clones primed by pathogens or vaccines. Science 2015; 347:400-6.
153. Nakayamada S, Kanno Y, Takahashi H et al. Early Th1 cell differentiation is marked by a Tfh cell-like transition. Immunity 2011; 35:919-31.
154. Linterman MA, Rigby RJ, Wong RK et al. Follicular helper T cells are required for systemic autoimmunity. J Exp Med 2009; 206:561-76.
155. Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly - TFH cells in human health and disease. Nat Rev Immunol 2013; 13:412-26.
156. Onengut-Gumuscu S, Chen WM, Burren O et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet 2015; 47:381-6.
157. Locci M, Havenar-Daughton C, Landais E et al. Human circulating PD-(+)1CXCR3(-)CXCR5(+) memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013; 39:758-69.
158. Cubas RA, Mudd JC, Savoye AL et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 2013; 19:494-9.
159. Bentebibel SE, Lopez S, Obermoser G et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 2013; 5:176ra32.
160. Morgan NG, Richardson SJ. Enteroviruses as causative agents in type 1 diabetes: loose ends or lost cause? Trends Endocrinol Metab 2014; 25:611-9.
161. Schneider DA, von Herrath MG. Potential viral pathogenic mechanism in human type 1 diabetes. Diabetologia 2014; 57:2009-18.